Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 2 N=5 Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease
N/A N=81 Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Skin Cancer · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31
Phase 3 N=198 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Phase 2 N=19 Cabozantinib and Nivolumab for Carcinoid Tumors
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Phase 2 N=36 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
N/A N=402 HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Phase 1 N=11 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
Phase 2 N=45 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
Phase 2 N=23 CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Pancreatic Cancer
Primary: Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects — 10; 1000…
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 2 N=43 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months